Information needs for medication coverage decisions in a state Medicaid program.

Area of Science:

• Health economics
• Pharmaceutical policy
• Health services research

Background:

• Health plans balance innovation access with cost containment.
• California's Medicaid program (Medi-Cal) serves a large, diverse mentally ill population.
• Medi-Cal utilizes a Therapeutic Class Review (TCR) process for pharmaceutical technology assessment.

Purpose of the Study:

• Describe Medi-Cal's TCR information for antidepressants.
• Detail Medi-Cal's individual petition review for antipsychotics.
• Synthesize experiences into policy recommendations for improved coverage decisions.

Main Methods:

• Collaborative evidence generation between Medi-Cal and pharmaceutical manufacturers.
• Analysis of Medi-Cal recipient needs and current treatment quality.
• Evaluation of cost-effectiveness for new pharmaceutical treatments.

Main Results:

• A substantial body of evidence was developed through collaboration.
• Insights were gained into Medi-Cal recipient needs and treatment effectiveness.
• Prospects for cost-effective introduction of novel treatments were assessed.

Conclusions:

• Medi-Cal employs a structured process for evaluating new medicines.
• The TCR process enhances understanding of coverage decision-makers' needs.
• Recommendations include increased surveillance and early clinical trial integration.